MEI Pharma Inc. filed SEC Form 8-K: Shareholder Director Nominations

$MEIP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MEIP alert in real time by email
8-K
false000126210400012621042024-11-222024-11-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2024

 

 

MEI Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-41827

51-0407811

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

9920 Pacific Heights Blvd.,

Suite 150

 

San Diego, California

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: 858 369-7100

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00000002 par value

 

MEIP

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.08 Shareholder Director Nominations

On November 22, 2024, MEI Pharma, Inc. (the “Company”) announced that the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) will be held on January 30, 2025. The Company’s stockholders of record as of the close of business on December 9, 2024 shall be entitled to notice of and to vote at the 2025 Annual Meeting. The Company has set a deadline, as set forth in the following paragraph, for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for inclusion in the Company’s proxy materials for the 2025 Annual Meeting. Pursuant to the rules of the Securities and Exchange Commission (“SEC”), the Company is providing notice of the deadlines for such proposals by means of this Current Report on Form 8-K.

Any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting in accordance with Rule 14a-8 must be delivered to, or mailed and received at, the Company’s principal executive offices at 9920 Pacific Heights Blvd., Suite 150, San Diego, California 92121 on or before the close of business on [December 10, 2024], which is the [51st] day prior to January 30, 2025 and which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials prior to the 2025 Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting must also comply with all applicable SEC rules.

 

There is a separate submission period applicable to the submission by stockholders of notice of a director nomination or a stockholder proposal outside of the processes of Rule 14a-8. Under the Company’s Sixth Amended and Restated Bylaws, such a nomination or proposal must be received by the Secretary of the Company not later than the 90th day, nor earlier than the 120th day, prior to the first anniversary of the preceding year’s annual meeting, so long as the current year’s meeting is not greater than 30 days before or greater than 60 days after the anniversary date of the preceding year’s meeting. The Company’s 2024 Annual Meeting of Stockholders was held on December 18, 2024. The 2025 Annual Meeting is to be held fewer than 60 days following the first anniversary of such meeting. Therefore, the deadline for receipt of notice of such a nomination or proposal previously disclosed by the Company, September 18, 2024, remains applicable. Accordingly, such deadline by which notice must have been received at the Company’s executive offices to be considered timely has passed.
 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MEI PHARMA, INC.

 

 

 

 

Date:

November 25, 2024

By:

/s/ Justin J. File

 

 

 

Justin J. File
Acting Chief Executive Officer, Chief Financial Officer and Secretary

 


Get the next $MEIP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MEIP

DatePrice TargetRatingAnalyst
7/23/2024Buy → Hold
Laidlaw
3/25/2022$4.00 → $1.00Buy → Hold
Jefferies
3/25/2022$13.00 → $2.00Overweight → Equal Weight
Wells Fargo
3/25/2022$6.00 → $2.00Buy → Hold
Stifel
2/3/2022$4.00Buy
Jefferies
More analyst ratings

$MEIP
Press Releases

Fastest customizable press release news feed in the world

See more
  • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

    Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

    Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Reports Fiscal Year End 2024 Cash Position

    Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MEIP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MEIP
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MEIP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MEIP
SEC Filings

See more

$MEIP
Leadership Updates

Live Leadership Updates

See more
  • MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

    MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MEIP
Financials

Live finance-specific insights

See more
  • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

    Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

    Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MEI Pharma Reports Fiscal Year End 2024 Cash Position

    Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MEIP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more